摘要
目的 探讨雷公藤多苷片联合阿达木单抗注射液治疗强直性脊柱炎患者的疗效。方法 回顾性选取强直性脊柱炎患者52例,根据其治疗方案分为联合组(n=25)和参照组(n=27)。参照组采用40 mg的阿达木单抗注射液皮下注射治疗,隔周给药1次,共治疗3个月。联合组在参照组的基础上予以雷公藤多苷片口服治疗,20 mg/次,3次/d,连续治疗3个月。评价比较两组疗效。治疗前后均检测比较两组血清转化生长因子-β(transforming growth factor-β,TGF-β)、白介素-6(interleukin-6,IL-6)、白介素-17(interleukin-17,IL-17)和白介素-23(interleukin-23,IL-23)水平、血浆C反应蛋白(C-reactive protein,CRP)水平及红细胞沉降率(erythrocyte sedimentation rate,ESR)水平。统计比较两组不良反应发生率。结果 联合组治疗总有效率为96.00%(24/25),高于参照组的70.37%(19/27),差异有统计学意义(P<0.05)。两组治疗前炎症因子和ESR水平比较差异无统计学意义(P> 0.05),与同组治疗前比较和两组治疗后组间比较,患者的血清TGF-β、IL-6、IL-17和IL-23水平、血浆CRP水平及ESR水平均降低,差异有统计学意义(P <0.05)。与参照组比较,联合组治疗后的血清TGF-β、IL-6、IL-17和IL-23水平、血浆CRP水平及ESR水平均较低,差异有统计学意义(P <0.05)。两组不良反应发生率比较差异无统计学意义(P> 0.05)。结论 雷公藤多苷片联合阿达木单抗注射液治疗强直性脊柱炎可有效改善疗效和维持免疫内环境稳定,且安全可靠。
Objective To explore the efficacy of tripterygium wilfordii polyglycoside tablets combined with adamumab injection in the treatment of ankylosing spondylitis. Methods A total of 52 patients with ankylosing spondylitis were retrospectively selected and divided into combined group(n =25) and reference group(n =27) according to their treatment plan. The control group was treated with 40 mg adamuzumab injection subcutaneously, once every other week for 3 months. Combined group was additionally given oral treatment of tripterygium wilfordii polyglycoside tablets, 20 mg/time, 3 times/day, for 3 consecutive months. The efficacy of the two groups was evaluated and compared. Serum levels of transforming growth factor-β(TGF-β), interleukin-6(IL-6), interleukin-17(IL-17) and interleukin-23(IL-23), C-reactive protein(CRP) and erythrocyte sedimentation rate(ESR) were detected and compared before and after treatment. The incidence of adverse reactions was statistically compared between the two groups. Results The effective rate in combination group was 96.00%(24/25), which was higher than that in reference group 70.37%(19/27), the difference was statistically significant(P < 0.05). There was no significant difference in the levels of inflammatory factors and erythrocyte sedimentation rate between 2 groups before treatment(P > 0.05). Compared with before treatment and between 2 groups after treatment, the levels of serum TGF-β, IL-6, IL-17 and IL-23, as well as the levels of CRP and ESR in patients were decreased, the difference was statistically significant(P < 0.05). Compared with the control group, the levels of serum TGF-β, IL-6, IL-17 and IL-23, plasma CRP level and ESR level in combined group were significantly lower after treatment, the difference was statistically significant(P < 0.05). There was no significant difference in the incidence of adverse reactions between two groups(P > 0.05). Conclusion Tripterygium wilfordii polyglycoside tablets combined with adamumab injection can effectively improve the curative effect and maintain the stability of immune internal environment in the treatment of ankylosing spondylitis, and it is safe and reliable.
作者
方荔玮
卓少逸
林桂锋
潘立香
FANG Liwei;ZHUO Shaoyi;LIN Guifeng;PAN Lixiang(Department of Geriatrics,Putian First Hospital,Putian Fujian 351000,China;Department of General Practice,Putian First Hospital,Putian Fujian 351000,China)
出处
《中国卫生标准管理》
2022年第5期134-137,共4页
China Health Standard Management
关键词
雷公藤多苷片
联合
阿达木单抗注射液
强直性脊柱炎
疗效
红细胞沉降率
tripterygium wilfordii polyglycosides tablet
the joint
adamuzumab injection
ankylosing spondylitis
the curative effect
erythrocyte sedimentation rate
